Literature DB >> 11094117

Vertigo in MS: utility of positional and particle repositioning maneuvers.

E M Frohman1, H Zhang, R B Dewey, K S Hawker, M K Racke, T C Frohman.   

Abstract

A 4-year experience with new-onset vertigo in a university-based MS population was retrospectively reviewed. Of 1,153 patients with MS, 25 could be clinically evaluated during the vertiginous episode. Of these, 13 (52%) were diagnosed with benign paroxysmal positioning vertigo and eight (32%) had acute MS exacerbations with corresponding lesions within the brainstem. All patients diagnosed with benign paroxysmal positioning vertigo were treated successfully with particle repositioning maneuvers.

Entities:  

Mesh:

Year:  2000        PMID: 11094117     DOI: 10.1212/wnl.55.10.1566

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Validation of the Comprehensive International Classification of Functioning, Disability, and Health Core Set for multiple sclerosis from the perspective of physicians.

Authors:  Stephanie Berno; Michaela Coenen; Andreas Leib; Alarcos Cieza; Jürg Kesselring
Journal:  J Neurol       Date:  2012-01-24       Impact factor: 4.849

2.  Symptomatic therapy in multiple sclerosis.

Authors:  Teresa C Frohman; Wanda Castro; Anjali Shah; Ardith Courtney; Jeffrey Ortstadt; Scott L Davis; Diana Logan; Thomas Abraham; Jaspreet Abraham; Gina Remington; Katherine Treadaway; Donna Graves; John Hart; Olaf Stuve; Gary Lemack; Benjamin Greenberg; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

Review 3.  Autoimmune vertigo: an update on vestibular disorders associated with autoimmune mechanisms.

Authors:  Francesca Yoshie Russo; Massimo Ralli; Daniele De Seta; Patrizia Mancini; Alessandro Lambiase; Marco Artico; Marco de Vincentiis; Antonio Greco
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

4.  Multiple sclerosis as a cause of the acute vestibular syndrome.

Authors:  J H Pula; D E Newman-Toker; J C Kattah
Journal:  J Neurol       Date:  2013-02-08       Impact factor: 4.849

5.  Some aspects of balance disorder in patients with multiple sclerosis.

Authors:  Adnan Burina; Osman Sinanović; Dzevdet Smajlović; Mirjana Vidović; Fuad Brkić
Journal:  Bosn J Basic Med Sci       Date:  2008-02       Impact factor: 3.363

Review 6.  Medical and Nonstroke Neurologic Causes of Acute, Continuous Vestibular Symptoms.

Authors:  Jonathan A Edlow; David E Newman-Toker
Journal:  Neurol Clin       Date:  2015-08       Impact factor: 3.787

7.  Epley manoeuvre for posterior semicircular canal benign paroxysmal positional vertigo in people with multiple sclerosis: protocol of a randomised controlled trial.

Authors:  Cristina García-Muñoz; María-Dolores Cortés-Vega; Juan Carlos Hernández-Rodríguez; Rocio Palomo-Carrión; Rocío Martín-Valero; María Jesús Casuso-Holgado
Journal:  BMJ Open       Date:  2021-03-18       Impact factor: 2.692

8.  Immersive Virtual Reality and Vestibular Rehabilitation in Multiple Sclerosis: Case Report.

Authors:  Cristina García-Muñoz; María-Dolores Cortés-Vega; Juan-Carlos Hernández-Rodríguez; Lourdes M Fernández-Seguín; Isabel Escobio-Prieto; María Jesús Casuso-Holgado
Journal:  JMIR Serious Games       Date:  2022-02-16       Impact factor: 3.364

9.  Efficacy of Repositioning Therapy in Patients With Benign Paroxysmal Positional Vertigo and Preexisting Central Neurologic Disorders.

Authors:  Chih-Chung Chen; Hsiao-Shan Cho; Hsun-Hua Lee; Chaur-Jong Hu
Journal:  Front Neurol       Date:  2018-06-29       Impact factor: 4.003

10.  Vestibular rehabilitation in multiple sclerosis: study protocol for a randomised controlled trial and cost-effectiveness analysis comparing customised with booklet based vestibular rehabilitation for vestibulopathy and a 12 month observational cohort study of the symptom reduction and recurrence rate following treatment for benign paroxysmal positional vertigo.

Authors:  J Marsden; M Pavlou; R Dennett; A Gibbon; R Knight-Lozano; L Jeu; C Flavell; J Freeman; D E Bamiou; C Harris; A Hawton; E Goodwin; B Jones; S Creanor
Journal:  BMC Neurol       Date:  2020-11-27       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.